Ischemic Stroke Hospitalized
Conditions
Keywords
Fabry disease, Screening, Ischemic stroke
Brief summary
Fabry disease is a genetic disease due to an enzymatic deficit. A screening of this disease allows patients to benefit from an enzyme replacement therapy and prevent the occurrence of life threatening manifestations such as an ischemic stroke. The purpose of the study is to determinate the prevalence of Fabry disease in a population of male patients hospitalized for an ischemic stroke. This study, with a screening of Fabry disease, allows the patients to make a precise diagnosis of their ischemic stroke and to facilitate the screening of the other members at the facility.
Interventions
PROCEDUREBlood sample
Ischemic stroke hospitalized
Sponsors
University Hospital, Clermont-Ferrand
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
28 Days to 55 Years
Healthy volunteers
No
Inclusion criteria
* Hospitalized ischemic stroke * Written and signed informed consent from patient or legal representative
Exclusion criteria
* Patients belonging to a family which has a Fabry disease's diagnosis confirmed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fabry disease's screening (Positive microdosage confirmed by a macrodosage) | Positive microdosage confirmed by a macrodosage |
Secondary
| Measure | Time frame |
|---|---|
| Describe and compare the characteristics of patients affected by Fabry disease and patients who are not affected Identify clinical and neuroradiological predictive elements of Fabry disease | patients affected by Fabry disease |
Countries
France
Outcome results
None listed